eligibility_summary
Adults (≥18) with advanced/metastatic solid tumors post progression/intolerance/ineligible/refuse SOC. Part A: NSCLC, breast, KRAS‑WT CRC, head & neck. Part B: EGFR‑mutant NSCLC or other tumors sensitive in Part A. Require RECIST‑measurable disease, ECOG 0–1, life expectancy >12 wks. Exclude active/uncontrolled CNS mets or meningitis, unresolved >G1 AEs, serious illness. Washouts: investigational/other therapy 4 wks, oral FP/small molecules or palliative RT/local 2 wks, major surgery 4 wks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05948865 tests CPO301 (SYS6010), an EGFR-targeting antibody–drug conjugate (ADC). Type/mechanism: a monoclonal antibody binds the EGFR antigen on tumor cells, the ADC is internalized, and a linked cytotoxic payload is released intracellularly to kill the cancer cell (specific payload not stated). Given IV every 3 weeks in Phase 1 dose escalation/expansion. Targets: EGFR-expressing solid tumors and EGFR-mutant cohorts, focusing on the EGFR/ErbB signaling axis and EGFR-overexpressing epithelial tumor cells. Tumor types include NSCLC (especially EGFR-mutant), head and neck, KRAS–wild-type colorectal, and breast cancers.